ライフサイエンスコーパス: viral shedding

1 n healing, pain resolution, and cessation of viral shedding).

2 sulted in different degrees of pathology and viral shedding.

3 l reactivation by explantation or peripheral viral shedding.

4 t seen in convalescent mice eliminated nasal viral shedding.

5 ant increase in the risk of complications or viral shedding.

6 loss of lesion pain and time to cessation of viral shedding.

7 10 animals fed intravenous TPN had continued viral shedding.

8 ques and may be useful in evaluation genital viral shedding.

9 integral features of CMV pneumonitis but not viral shedding.

10 ection causes recurrent lesions and frequent viral shedding.

11 and lower respiratory tract and much reduced viral shedding.

12 ved survival and reduced genital lesions and viral shedding.

13 ot serum antibodies, correlated with reduced viral shedding.

14 vival but did not reduce genital lesions and viral shedding.

15 th the throat viral load and the duration of viral shedding.

16 lted in different degrees of lung damage and viral shedding.

17 g resistance, most probably due to prolonged viral shedding.

18 DNAemia and limited tissue dissemination and viral shedding.

19 thus controlling both recurrent lesions and viral shedding.

20 n subjects with similar illness severity and viral shedding.

21 ce remain infected for life, with periods of viral shedding.

22 n the mid-1980s showed nearly constant fecal viral shedding.

23 because lesions are accompanied by frequent viral shedding.

24 viral titers and decreasing the duration of viral shedding.

25 duration (P = .001) and titer (P = .005) of viral shedding.

26 ive for adenovirus (incidence 23.5%), 23 for viral shedding, 23 for infections.

27 train EDIM) induced complete protection from viral shedding after challenge for at least 6 weeks afte

28 partial protection, characterized by reduced viral shedding after challenge.

29 vaccines were well tolerated, and prolonged viral shedding after LAIV was not detected.

30 indication of ISS efficacy, the magnitude of viral shedding also was significantly reduced in ISS-tre

31 ys (43.0%; 95% CI, 39.8%-46.5%) with genital viral shedding among persons with symptomatic genital HS

32 ses have similar characteristics in terms of viral shedding and clinical illness.

33 Days of viral shedding and IL-6 but not IL-8 concentrations were

34 es protective immunity that can reduce acute viral shedding and latent infection in a mouse genital m

35 e cohort of 128 HSV-2-infected persons whose viral shedding and lesion frequency was measured by dail

36 Viral shedding and nasal IgA levels were measured in add

37 Since most cases of human viral shedding and reactivation are not associated with

38 The viral shedding and susceptibility to infection we observ

39 ay 3 in plasma, day 4 in nasal fluids), when viral shedding and symptoms were subsiding.

40 virus (HSV) infection, but they cannot stop viral shedding and transmission.

41 easures were frequency of infection based on viral shedding and/or seroconversion (prophylaxis) or qu

42 n continued protection against infection, no viral shedding, and boosting of the immune response.

43 Subjects were followed up for clinical take, viral shedding, and immune responses.

44 with lower [corrected] symptom scores, less viral shedding, and improved health, activity, and sleep

45 e incidence of reactivation and asymptomatic viral shedding, and limit morbidity and mortality from a

46 ad more severe disease/complications, longer viral shedding, and more antiviral resistance while demo

47 d mild to moderate diarrhea, lower titers of viral shedding, and no mortality, whereas the icPC22A vi

48 Subjects were monitored for symptoms, viral shedding, and safety, including cytokine measureme

49 d by survival, weight loss, activity scores, viral shedding, and seroconversion.

50 mab decreased the duration of RV infections, viral shedding, and the risk of RV illnesses.

51 CD8(+) T cells in ss7(-/-) animals prolonged viral shedding, and transfer of immune ss7(-/-) CD8(+) T

52 time after infection, but data on long-term viral shedding are lacking.

53 Prolonged viral shedding, as observed in immunocompromised individ

54 ril in decreasing the signs and symptoms and viral shedding associated with a viral respiratory infec

55 mock-treated HEV-infected pigs cleared fecal viral shedding at 8 wk postinfection.

56 n treatment showed a significant decrease in viral shedding at day 3 relative to monotherapy, this di

57 The transmission of herpesviruses depends on viral shedding at mucosal surfaces.

58 though CXCL1 knockout mice display increased viral shedding at the cornea.

59 seroconversion (prophylaxis) or quantitative viral shedding based on titers and duration of virus rec

60 Greater reductions in viral shedding, based on median tissue culture infective

61 allowing for detection of a 50% reduction in viral shedding between the study treatments.

62 We compared the patterns of influenza viral shedding between these groups.

63 buffer, compared with normal saline, reduced viral shedding by 1 log unit (10(3) vs. 10(4) 50% tissue

64 titers by 2.0 log10, the median duration of viral shedding by 3 days, and the frequency of febrile i

65 ter 7 times normal was needed to lower nasal viral shedding by 98%.

66 on of oseltamivir treatment with duration of viral shedding by polymerase chain reaction or with the

67 Viral shedding ceased in 13 (87%) of 15 cidofovir-treate

68 ract disease (LRD), hypoxemia, and prolonged viral shedding compared with seasonal influenza A.

69 refed enterally for 5 days were positive for viral shedding, compared with 8 of 12 matched TPN-fed an

70 RNA throughout lactation and more-consistent viral shedding, compared with mothers who did not transm

71 ht reflect differences in incubation period, viral shedding, contact, or susceptibility.

72 Frequent viral shedding contributed to a high rate of infection,

73 ross all studies, suggesting an adherence of viral shedding counts to the Pareto Principle.

74 o analyze jointly both symptom reporting and viral shedding data from a three-armed study of influenz

75 ion from respiratory samples, variability in viral shedding duration, lack of effective therapy, and

76 The nature of influenza viral shedding during naturally acquired infection is no

77 enza disease in 69% of individuals with mean viral shedding for 4-5 days and significant rises in con

78 ients with 2009 H1N1 influenza pneumonia had viral shedding for over 5 weeks despite therapy with ose

79 olling and will evaluate the effect of 4b on viral shedding from sanctuary sites in EBOV survivors.

80 or did such therapy decrease the duration of viral shedding from the nasopharynx among patients with

81 d killed 40 hours postchallenge to determine viral shedding from the upper respiratory tract.

82 al virus and killed at 40 hours to determine viral shedding from the upper respiratory tract.

83 Prolonged viral shedding has been reported in semen, suggesting th

84 The relationships between host factors, viral shedding, illness severity, and antibody response

85 There was no viral shedding in any animal fed via the gastrointestina

86 contrast, there was no difference in ocular viral shedding in B6-E mice transplanted with 129 or B6

87 of the placenta and genital tract; increased viral shedding in breast milk from inflammation of breas

88 can establish chronic infections with active viral shedding in healthy humans but whether persistence

89 The frequency of viral shedding in men with genital herpes appears compar

90 t of fever, lesion appearance, peak viremia, viral shedding in nasal and oral swabs, peak cytokine le

91 aled statistically significant reductions in viral shedding in nasal secretions (P<.001), nasal mucus

92 No clinical signs of FMD, viremia, or viral shedding in nasal swabs was found in the Ad5-boIFN

93 Time to clinical resolution and change in viral shedding in nasopharyngeal specimens were the prim

94 ategies to reduce PV replication to diminish viral shedding in OPV recipients.

95 points were duration of clinical illness and viral shedding in patients treated less than and more th

96 The presence of influenza viral shedding in patients with influenza who have very

97 The timing and intensity of respiratory viral shedding in patients with MERS closely matches tha

98 or oseltamivir to reduce patient illness and viral shedding in people with influenza, in whom treatme

99 affects young children and causes prolonged viral shedding in saliva and urine.

100 er biopsies concurrent with the detection of viral shedding in stool, and NV antigen expression was o

101 irradiation, vaccinated mice showed reduced viral shedding in tears as well as a reduction in the in

102 erity of genital lesions and lower levels of viral shedding in the genital tract after HSV-2 challeng

103 Seropositivity for HSV-2 is associated with viral shedding in the genital tract, even in subjects wi

104 ecreased change from baseline viral load and viral shedding in the multiple-dose group compared with

105 eral nutrition-fed animals continued to have viral shedding in the nasal passages compared to one of

106 Treatment with 0.5 mg/kg HNK20 reduced viral shedding in the nose, throat, and lungs by 3-4 log

107 intestinal tissue viral titers and increased viral shedding in the stool.

108 o adrenergically induced reactivation, i.e., viral shedding in the tears, compared with rabbits infec

109 reports have describe high-level persistent viral shedding in the urine of infected patients, but th

110 nificant decreases in a composite serotype 2 viral shedding index after mOPV2 challenge.

111 on as measured by both recurrent disease and viral shedding into the genital tract.

112 oung children who acquire CMV have prolonged viral shedding into the urine and saliva, but whether th

113 Viral shedding is associated with a transient drop in th

114 e first 3 days of parotitis, suggesting that viral shedding is minimal after the first 3 days of symp

115 are common in the first 100 days after HCT, viral shedding lasts more than 3 weeks in half, and lowe

116 The rate of viral shedding measured by quantitative real-time fluore

117 Evaluation of viral shedding, nasal and serum cytokines, clinical illn

118 ease (3 to 4 logs) in ocular, but not nasal, viral shedding occurred during acute infection relative

119 No viral shedding occurred in the group immunised with BHPI

120 Peak viral shedding occurred on days 7-9 after infection.

121 They experienced 238 episodes of viral shedding, of which 23 (10%) were not accompanied b

122 therapy appears to be inadequate in reducing viral shedding or mortality once pneumonia is establishe

123 linic to demonstrate sustained depression of viral shedding or protection from recurrences.

124 s in living quarters and extended pharyngeal viral shedding over the course of several days.

125 zation could affect transmission by altering viral shedding patterns.

126 tal treatment did not influence asymptomatic viral shedding patterns.

127 Fecal viral shedding persisting for 8 days was detected by bot

128 However, viral shedding persists at high rates and copy numbers y

129 .6%]; P = 0.93), had significantly decreased viral shedding (positive cultures compared with total cu

130 ee serotypes and intestinal immunity (faecal viral shedding post-challenge) to serotype 2, analysed i

131 Viral shedding preceded symptoms by 12-24 hours and term

132 two tests was highest early in the course of viral shedding (r = 0.91, days 0 to 6), whereas during d

133 The overall viral shedding rate among men (n = 247) with evidence of

134 The total viral shedding rate in HSV-2-seropositive men was 5%; th

135 mmune responses to OPV but not the prolonged viral shedding required to form iVDPV.

136 Viral shedding, secretion weights, symptom scores, and c

137 Importantly, viral shedding significantly increased in pDC-deficient

138 e type I IFN receptor had minimal effects on viral shedding, suggesting that endogenous type I IFN si

139 sponses were noted during the peak period of viral shedding, suggesting that protection was due to sp

140 tion of a high Treg to Tconv ratio with high viral shedding suggests that the balance between regulat

141 with placebo, rimantadine treatment reduced viral shedding, systemic symptoms, and levels of IL-8.

142 nfluenza infection, aged mice have prolonged viral shedding that is presumably due to lower anti-infl

143 Reduced viral shedding titers were correlated with significantly

144 /77 as defined by substantial differences in viral shedding trajectories.

145 Molecular viral shedding values follow symptom scores, but timing

146 Median duration of viral shedding was 3 weeks; prolonged shedding of at lea

147 e was analyzed by in situ hybridization, and viral shedding was assessed by quantitative PCR.

148 Viral shedding was associated with increases in local an

149 In one case, viral shedding was cleared without evidence of maribavir

150 Importantly, the frequency of recurrent viral shedding was considerably reduced in GEN-003/MM-2-

151 eatinine clearances were lower at times when viral shedding was detected (P=0.038).

152 Ten LAIV recipients shed virus; the latest viral shedding was detected 7 days after vaccination.

153 Viral shedding was detected in only six (6%) of 101 part

154 Viral shedding was measured at 42 hours after challenge.

155 Viral shedding was monitored by tear film cultures.

156 Viral shedding was not influenced by primary diagnosis,

157 Prolonged viral shedding was not noted, and the patients recovered

158 he patients improved promptly, and prolonged viral shedding was not noted.

159 In one child, viral shedding was observed in two stools obtained 91 da

160 Surprisingly, H1N1pdm viral shedding was reduced in animals vaccinated with MV

161 The duration of viral shedding was reduced, however, among children who

162 ly lower, and the duration of nasopharyngeal viral shedding was shorter in some vaccinated monkeys af

163 imens from HSV-2 positive women, genital HIV viral shedding was similar during symptomatic and asympt

164 Predictors of viral shedding were determined using backwards selection

165 Mean days of cutaneous viral shedding were reduced from 3.3 in the placebo grou

166 Both duration and peak titer of viral shedding were reduced in MVA recipients.

167 The relative risk of viral shedding with pritelivir, as compared with placebo

168 p (n = 13), and the median (IQR) duration of viral shedding with therapy was reduced from 107 (83-131

169 al herpes, and we compared their patterns of viral shedding with those in a similar cohort of 90 subj